Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DeMarini

Showing results (301-310 of 314) with videos related to

Pageof 32
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 1, 1996
The glutathione S-transferase M1 (GSTM1) null genotype and benzidine-associated bladder cancer, urine mutagenicity, and exfoliated urothelial cell DNA adductsN Rothman, R B Hayes, T V Zenser, et al.
The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2008
N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part IKevin S Thorneloe, Anthony C Sulpizio, Zuojun Lin, et al.
Environmental and Molecular Mutagenesis|July 31, 2021
Elevated urinary mutagenicity among those exposed to bituminous coal combustion emissions or diesel engine exhaustJason Y Y Wong, Roel Vermeulen, Yufei Dai, et al.
Cell Reports|September 24, 2013
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanomaJessie Villanueva, Jeffrey R Infante, Clemens Krepler, et al.
The Lancet. Oncology|March 30, 2026
Carcinogenicity of tris(chloropropyl) phosphate, butyraldehyde, and cumyl hydroperoxideDirk W Lachenmeier, Victoria H Arrandale, David M DeMarini, et al.
Plos One|June 12, 2013
The application of the Ten Group classification system (TGCS) in caesarean delivery case mix adjustment. A multicenter prospective studyGianpaolo Maso, Salvatore Alberico, Lorenzo Monasta, et al.
Biomed Research International|July 19, 2013
Interinstitutional variation of caesarean delivery rates according to indications in selected obstetric populations: a prospective multicenter studyGianpaolo Maso, Monica Piccoli, Marcella Montico, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 32

Showing results (301-310 of 314) with videos related to

Sort By:
Pageof 32
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 1, 1996
The glutathione S-transferase M1 (GSTM1) null genotype and benzidine-associated bladder cancer, urine mutagenicity, and exfoliated urothelial cell DNA adductsN Rothman, R B Hayes, T V Zenser, et al.
The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2008
N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part IKevin S Thorneloe, Anthony C Sulpizio, Zuojun Lin, et al.
Environmental and Molecular Mutagenesis|July 31, 2021
Elevated urinary mutagenicity among those exposed to bituminous coal combustion emissions or diesel engine exhaustJason Y Y Wong, Roel Vermeulen, Yufei Dai, et al.
Cell Reports|September 24, 2013
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanomaJessie Villanueva, Jeffrey R Infante, Clemens Krepler, et al.
The Lancet. Oncology|March 30, 2026
Carcinogenicity of tris(chloropropyl) phosphate, butyraldehyde, and cumyl hydroperoxideDirk W Lachenmeier, Victoria H Arrandale, David M DeMarini, et al.
Plos One|June 12, 2013
The application of the Ten Group classification system (TGCS) in caesarean delivery case mix adjustment. A multicenter prospective studyGianpaolo Maso, Salvatore Alberico, Lorenzo Monasta, et al.
Biomed Research International|July 19, 2013
Interinstitutional variation of caesarean delivery rates according to indications in selected obstetric populations: a prospective multicenter studyGianpaolo Maso, Monica Piccoli, Marcella Montico, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 32